MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

摘要: In phase II and III trials of gadoteridol (Gd-HP-D03A), a new nonionic, low-osmolar contrast agent, 40 patients with intracranial neoplasms underwent magnetic resonance (MR) imaging experimental doses 0.05-0.3 mmol/kg. Fifteen also studies the standard dose (0.1 mmol/kg) gadopentetate dimeglumine. Both dimeglumine appear to have similar effect when given in equal mmol/kg, n = 5). Lesion enhancement delineation were better at higher (0.2 or 0.3 7) worse lower (0.05 3). Quantitative analysis 10 lesions examined identical protocols revealed directly proportional relationship (r .975) between lesion ratio over range Phantom experiments support clinical results. Improved enhancement, detection, central nervous system (CNS) resulting from increased injected d...